FibroBiologics files for first human trial of novel psoriasis therapy
FibroBiologics (NASDAQ:FBLG) took a decisive step toward clinical-stage operations on Wednesday, filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1/2 trials for its lead psoriasis candidate, CYPS317.






-640x358.jpg&w=3840&q=75)



